Aiming for "Global R&BD Group"
Intron Bio is developing new drugs for (1) human subjects and (2) disease treatment drugs.
(3) With the direction and goal of First-in-Class (MoA_based),
Aiming to become a “global R&BD group” that is not limited to simple research but aims for business development,
As well as continuously investing in building a number of new biopharmaceutical pipelines,
We are gradually transferring (L/O) technology to domestic and overseas markets for various new drug pipelines.
Through this, we will gradually increase our value as a new biopharmaceutical company.